Evidence map›Paper›PMID 36612090›Full record

ArticleCancers2022

Prospective Assessment of Tumour Burden and Bone Disease in Plasma Cell Dyscrasias Using DW-MRI and Exploratory Bone Biomarkers.

Gaurav Agarwal, Guido Nador, Sherin Varghese, Hiwot Getu, Charlotte Palmer, Edmund Watson, Claudio Pereira, Germana Sallemi, Karen Partington, Neel Patel and 12 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 3 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 5 institutions in 1 country.

Gaurav AgarwalDepartment of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford OX3 7LE, UK.
Guido NadorDepartment of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford OX3 7LE, UK.
Sherin VargheseDepartment of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford OX3 7LE, UK.
Hiwot GetuDepartment of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford OX3 7LE, UK.
Charlotte PalmerBotnar Research Centre, The Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford OX3 7LD, UK.
Edmund WatsonBotnar Research Centre, The Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford OX3 7LD, UK.
Claudio PereiraBotnar Research Centre, The Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford OX3 7LD, UK.
Germana SallemiBotnar Research Centre, The Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford OX3 7LD, UK.
Karen PartingtonDepartment of Radiology, Oxford University Hospitals NHS Foundation Trust, Oxford OX3 9DU, UK.
Neel PatelDepartment of Radiology, Oxford University Hospitals NHS Foundation Trust, Oxford OX3 9DU, UK.
Rajkumar SoundarajanOxford Centre for Magnetic Resonance, Radcliffe Department of Medicine, University of Oxford, Oxford OX3 9DU, UK.ORCID 0000-0002-1506-2672
Rebecca MillsOxford Centre for Magnetic Resonance, Radcliffe Department of Medicine, University of Oxford, Oxford OX3 9DU, UK.
Richard BrouwerDepartment of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford OX3 7LE, UK.
Marina MaritatiBotnar Research Centre, The Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford OX3 7LD, UK.ORCID 0000-0001-9437-5070
Aarti ShahDepartment of Radiology, Hampshire Hospitals NHS Foundation Trust, Hampshire SO22 5DG, UK.
Delia PeppercornDepartment of Radiology, Hampshire Hospitals NHS Foundation Trust, Hampshire SO22 5DG, UK.
Udo OppermannOxford Translational Myeloma Centre, Oxford OX3 7LD, UK.
Claire M EdwardsBotnar Research Centre, The Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford OX3 7LD, UK.
Christopher T RodgersDepartment of Clinical Neurosciences, University of Cambridge, Cambridge CB2 0QQ, UK.ORCID 0000-0003-1275-1197
Muhammad Kassim JavaidBotnar Research Centre, The Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford OX3 7LD, UK.
Sarah GoodingDepartment of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford OX3 7LE, UK.
Karthik RamasamyDepartment of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford OX3 7LE, UK.
Nuffield Orthopaedic Centre · GBOxford University Hospitals NHS Trust · GBUniversity of Oxford · GBHampshire Hospitals NHS Foundation Trust · GBUniversity of Cambridge · GB

Funding

Amgen Pharmaceuticals ISS: 20167888Medical Research Council MR/V037439/1
6 · The paper itself

Abstract

Novel biomarkers for tumour burden and bone disease are required to guide clinical management of plasma cell dyscrasias. Recently, bone turnover markers (BTMs) and Diffusion-Weighted Magnetic Resonance Imaging (DW-MRI) have been explored, although their role in the prospective assessment of multiple myeloma (MM) and monoclonal gammopathy of undetermined significance (MGUS) is unclear. Here, we conducted a pilot observational cohort feasibility study combining serum BTMs and DW-MRI in addition to standard clinical assessment. Fifty-five patients were recruited (14 MGUS, 15 smouldering MM, 14 new MM and 12 relapsed MM) and had DW-MRI and serum biomarkers (P1NP, CTX-1, ALP, DKK1, sclerostin, RANKL:OPG and BCMA) measured at baseline and 6-month follow-up. Serum sclerostin positively correlated with bone mineral density (

Indexed as

biomarkersbone diseaseDW-MRIMGUSmultiple myeloma

Identifiers

PMID36612090
PMCPMC9817825
OpenAlexW4313247311

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.